Pharma Focus Asia

AstraZeneca Invests US$300 million to Open New Manufacturing Facility in Maryland, USA

Introduction:

AstraZeneca invests US$300 million to open a state-of-the-art manufcaturing facility in Maryland, USA.

Features:

The Rockville facility aims to enhance its manufacturing capabilities to propel advancements in next-generation cell therapy research and development.

The facility will primarily concentrate on manufacturing essential components for cancer trials and introducing commercial cell therapy platforms.

The initial phase will see the creation of over 150 highly skilled positions, primarily dedicated to manufacturing T-cell therapies for global clinical trials. As the site grows, there is a potential for it to broaden its focus and provide support for additional disease areas.

The Rockville facility is set to become part of a global manufacturing and supply network consisting of nearly 30 sites across 16 countries, all either currently operational or under development. 

In the US, manufacturing sites prioritise the production of small molecules and biologics, leveraging cutting-edge pharmaceutical technology and development.

Specifications:

Name        AstraZeneca
Type          New Construction
Budget     US$300 million


 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024